Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Semma Therapeutics
Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.
Vertex will pay $320m to buy rival ViaCyte, which is developing stem cell therapies for type 1 diabetes, to complement internal work on VX-880, the firm announced.
Only nine weeks after US approval, Trikafta, which in theory can treat 90% of all patients with cystic fibrosis, is already Vertex's top-selling medicine.
Growth gaps and a desire to concentrate on a small number of therapeutic areas are expected to continue to drive M&A in 2020, but thought needs to be given to investing in data-driven and digital technologies, a new EY report says.
- Medical Devices
- Gene Therapy, Cell Therapy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.